board approved the transfer of its domestic branded generic pharmaceutical formulations business to wholly owned subsidiary Auropharm Limited for INR 143.21 crores on April 6, 2026. The business contributed Rs. 1,753.40 million in turnover (0.55% of consolidated turnover) and will be transferred as a slump sale on going concern basis. The strategic move aims to consolidate domestic pharmaceutical operations under the subsidiary for enhanced operational efficiency, with completion expected within 90 to 120 days. Please note that the information shared is intended solely for informational purposes and does not make any investment recommendations.